Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simeprevir + daclatasvir
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Simeprevir + daclatasvir is an oral combination regimen of two direct-acting antiviral agents used for the treatment of chronic hepatitis C virus (HCV) infection. Simeprevir is an HCV NS3/4A protease inhibitor that blocks viral replication by inhibiting the cleavage of the HCV polyprotein. Daclatasvir is an HCV NS5A inhibitor that interferes with viral RNA replication and virion assembly. This combination has been studied primarily in patients with genotype 1b infection and advanced liver disease, showing strong antiviral activity and a high rate of sustained virologic response (SVR12), though some risk of viral breakthrough exists[6][8]. Both drugs are administered orally once daily.
- Brand names
- DaklinzaOlysio
- Other names
- simeprevir + daclatasvir
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on simeprevir + daclatasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simeprevir + daclatasvir.